Welcome to Ligand Pharmaceuticals

Ligand is a high-growth company with economic rights to some of the world's most important medicines.

Portfolio
Technologies
Licensing Opportunities

Investor Relations

View Investor Relations

Latest News

Ligand Reports First Quarter 2016 Financial Results

Read More

Ligand Acquires Portfolio of Synthetic Royalty and Milestone Rights from CorMatrix® Cardiovascular for $17.5 Million

Read More

Ligand Announces First Quarter 2016 Earnings Reporting Date and Participation in Four Upcoming Investor Conferences

Read More

Recent Events

Upcoming Events

Stock Snapshot

LGND
NASDAQ
Volume
Market Cap
Day Range
52-Week Range